Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse
Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.
You may also be interested in...
After a Phase III failure in refractory schizophrenia, Acadia has Phase II data showing efficacy in negative symptoms of the disease, an unmet need. It plans a pivotal study in 2020.
The company expects to file pimavanserin for the treatment of dementia-related psychosis in 2020, based on the results of a single positive Phase III trial.